Last year, we published an editorial in this journal, advocating the use of neoadjuvant treatment (NAT) in patients with breast cancer, especially for those bearing aggressive tumours (luminal B, triple-negative and HER2-positive subtypes).[@R1] With the recent publication of important practice-changing data, we argue now that the use of NAT is the only ethical strategy for around one-third of women with early breast cancer.

The first reason for using NAT is that it allows surgical de-escalation, as it increases the rates of breast-conserving surgery.[@R2] It may also avoid a full axillary dissection in selected patients who 'convert' from cN1 to a negative sentinel lymph-node biopsy.[@R3] Another very important reason is that it identifies patients at a higher risk of relapse, for whom additional 'salvage' options are now available. Two large meta-analyses have demonstrated that patients who do not achieve a pathological complete response (pCR) after NAT have worse long-term survival, especially in triple-negative breast cancer (TNBC) and HER2-positive disease.[@R4] Yet, it has recently been shown that their outcome may be improved by escalating post-NAT.

The CREATE-X trial, conducted in Asia, included both patients with oestrogen receptor (ER)-positive/HER2-negative disease and TNBC, who were randomised to receive standard postsurgical treatment either with or without capecitabine.[@R6] Among patients with TNBC, capecitabine significantly improved 5-year disease-free survival: it was 69.8% in the capecitabine group versus 56.1% in the control group (HR 0.58; 95% CI 0.39 to 0.87); it also improved overall survival (HR 0.52; 95% CI 0.30 to 0.90). In patients with ER-positive/HER2-negative disease, the HR for disease free-survival was more modest: 0.81 (95% CI 0.55 to 1.17). Despite concerns on the extrapolation of CREATE-X results to non-Asian patients, international guidelines adopted adjuvant capecitabine as a possible treatment for patients with TNBC and invasive residual disease after NAT.[@R7]

More recently, the KATHERINE trial randomised 1486 patients with residual invasive HER2-positive disease following NAT to adjuvant T-DM1 or trastuzumab for 14 cycles.[@R9] Results were impressive: the 3-year invasive disease-free survival rate was 88.3% in the T-DM1 group versus 77.0% in the trastuzumab group (HR 0.50; 95% CI 0.39 to 0.64), making it clear that these patients with suboptimal responses to standard chemotherapy and anti-HER2 monoclonal antibodies (trastuzumab ± pertuzumab) should receive adjuvant T-DM1 instead of continuing trastuzumab. Nonetheless, there is space for further improvement in the ER-negative/HER2-positive subgroup, as 3-year invasive disease-free survival rate was 82.1% with T-DM1. Overall survival data are still immature.

Of note, there are several ongoing phase III trials testing the postneoadjuvant use of other drugs in patients with residual disease after NAT, like the PENELOPE-B trial in ER-positive/HER2-negative patients (standard endocrine therapy with/without 1 year of palbociclib; ClinicalTrials.gov identifier: NCT01864746) or the SWOG S1418/NRG BR006 trial in TNBC (1 year of pembrolizumab or placebo; NCT02954874).

Considering the above results---and particularly those of the very robust international KATHERINE trial---we advocate that clinicians must use tumour's response to NAT as a way to tailor adjuvant treatment of patients with intermediate to high-risk HER2-positive disease or TNBC, instead of blindly prescribing chemotherapy and/or targeted agents after surgery.

NAT becomes the 'standard of care' for these women and not only an 'option' to discuss for the purpose of increasing the probability of less aggressive surgery, as it has an impact on disease-free survival and, possibly, on overall survival as well. A number of remaining questions will need to be addressed, like which adjuvant anti-HER2 therapy to prescribe to patients who achieve pCR after neoadjuvant chemotherapy with trastuzumab and pertuzumab and whether or not biomarkers evaluated after one or two courses of NAT might reliably identify patients who will not reach a pCR and who could benefit from an earlier introduction of a 'salvage' treatment.

The NAT strategy could also become a standard of care for high-risk luminal B disease in the near future, if it is demonstrated that those patients who do not achieve a pCR after NAT may benefit from the addition of targeted therapy to endocrine treatment. Beyond pCR 'yes or no', other prognostic markers can be used to identify high-risk patients, like the residual cancer burden[@R10] or the PEPI score.[@R11] More recently, prognostic markers like tumour-infiltrating lymphocytes in the residual tumour[@R12] or the persistence of circulating tumour DNA (ctDNA)[@R13] have also been explored. These markers may also be important for patients who achieve pCR, as we know that a part of these patients still relapse afterwards and we should find ways of identifying them.

Even though the use of NAT helps tailoring adjuvant therapy, in patients who do not achieve pCR (who are still the majority), the duration of neoadjuvant plus adjuvant treatment can be very long---for example, up to 18 months in HER2-positive disease. Thus, an earlier identification of patients who are benefiting or not from NAT is necessary in order to (de)escalate therapy accordingly. One possibility is the use of imaging during the course of NAT, like MRI[@R14] and/or ^18^F-FDG PET/CT,[@R16] which have shown to be associated with achievement of pCR. Other possibilities are measuring the drop of Ki67 after 2--4 weeks of treatment[@R18] or assessing the fall in ctDNA levels during NAT.[@R22] Today, however, there is no proven benefit of changing the type of regimen used throughout NAT according to these markers, but there are ongoing trials testing this hypothesis (ie, ALTERNATE \[NCT01953588\] and ADAPT HR+/HER2- \[NCT01779206\]).

It should also be realised that the use of NAT demands a highly organised team of pathologists, radiologists, surgeons, medical oncologists, radiation oncologists and other professionals specialised in breast cancer care. As already recommended by the European Society for Medical Oncology,[@R24] we are strong believers that the model of 'breast cancer units' should now be fully implemented in Europe and abroad, as failing to do so might compromise patients' survival.[@R25] A courageous way of accelerating its dissemination would be to restrict breast cancer treatment reimbursement to hospitals which have an accredited breast cancer unit.

In conclusion, we claim that patients with intermediate to high-risk TNBC or HER2-positive disease (≥T2 and/or lymph-node positive tumours) must receive NAT, as this strategy not only increases the chance of less aggressive surgery, but identifies patients who will benefit from 'salvage' adjuvant therapy with an impact on long-term outcomes.

**Funding:** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests:** MB: Travel expenses: Roche-Genentech. Research grants to the institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche-Genentech, Synthon, Radius, Servier. FR: Consultant (honoraria): Agendia. Research grant: Roche-Genentech. MJP: Board member of Radius. Consultant (honoraria): AstraZeneca, Lilly, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Camel-IDS, Crescendo Biologics, Periphagen, Huya, Debiopharm, PharmaMar, G1 Therapeutics, Menarini, Seattle Genetics, Immunomedics, Oncolytics. Research grants to the institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche-Genentech, Synthon, Radius, Servier.

**Patient consent for publication:** Not required.

**Provenance and peer review:** Not commissioned; internally peer reviewed.
